Peroxisomal branched chain fatty acid β-oxidation pathway is upregulated in prostate cancer

Prostate

Volumn 63, Issue 4, 2005, Pages 316-323

  Zha, Shan ^a   Ferdinandusse, Sacha ^d   Hicks, Jessica L ^b,c   Denis, Simone ^d   Dunn, Thomas A ^b   Wanders, Ronald J ^d   Luo, Jun ^b   De Marzo, Angelo M ^b,c   Isaacs, William B ^b,c,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

oxidation; Acyl CoA oxidase; D bifunctional protein; Peroxisome; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACYL COENZYME A OXIDASE; DEXTRO BIFUNCTIONAL PROTEIN; FATTY ACID; MESSENGER RNA; OXIDOREDUCTASE; PRISTANOYL COA OXIDASE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; PEROXISOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

17-HYDROXYSTEROID DEHYDROGENASES; ACYL-COA OXIDASE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENOYL-COA HYDRATASE; FATTY ACIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDRO-LYASES; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MULTIENZYME COMPLEXES; OXIDATION-REDUCTION; OXIDOREDUCTASES; PEROXISOMES; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER; UP-REGULATION;

EID: 18644382720     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20177     Document Type: Article

References (28)

1. Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, IJlst L. Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis 1999;22:442-487.
2. Seedorf U, Brysch P, Engel T, Schrage K, Assmann G. Sterol carrier protein X is peroxisomal 3-oxoacyl coenzyme A thiolase with intrinsic sterol carrier and lipid transfer activity. J Biol Chem 1994;269:21277-21283.
3. Ferdinandusse S, Denis S, van Berkel E, Dacremont G, Wanders RJ. Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier protein X (SCPx). Activity measurements in liver and fibroblasts using a newly developed method. J Lipid Res 2000;41:336-342.
4. Baumgart E, Vanhooren JC, Fransen M, Marynen P, Puype M, Vandekerckhove J, Leunissen JA, Fahimi HD, Mannaerts GP, Van Veldhoven PP. Molecular characterization of the human peroxisomal branched-chain acyl-CoA oxidase: cDNA cloning, chromosomal assignment, tissue distribution, and evidence for the absence of the protein in Zellweger syndrome. Proc Natl Acad Sci USA 1996;93:13748-13753.
5. Vanhooren JC, Marynen P, Mannaerts GP, Van Veldhoven PP. Evidence for the existence of a pristanoyl-CoA oxidase gene in man. Biochem J 1997;325(Pt 3):593-599.
6. Ferdinandusse S, Denis S, Clayton PT, Graham A, Rees JE, Allen JT, McLean BN, Brown AY, Vreken P, Waterham HR, Wanders RJ. Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 2000;24:188-191.
7. Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000;41:1890-1896.
8. Amery L, Fransen M, De Nys K, Mannaerts GP, Van Veldhoven PP. Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase in humans. J Lipid Res 2000;41:1752-1759.
9. Jiang Z, Woda BA, Yang XJ. Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer. JAMA 2002;287:3080-3081.
10. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002;62:2220-2226.
11. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-1670.
12. Zha S, Ferdinandusse S, Simone D, Wanders RJ, Ewing CM, Luo J, De Marzo A, Isaacs WB. Alpha-methylacyl-CoA racemase as an androgen independent growth modifier in prostate cancer. Cancer Res 2003;63:7365-7376.
13. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-8623.
14. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-408.
15. Jiang LL, Kobayashi A, Matsuura H, Fukushima H, Hashimoto T. Purification and properties of human D-3-hydroxyacyl-CoA dehydratase: Medium-chain enoyl-CoA hydratase is D-3-hydroxyacyl-CoA dehydratase. J Biochem (Tokyo) 1996;120:624-632.
16. van Grunsven EG, van Berkel E, IJlst L, Vreken P, de Klerk JB, Adamski J, Lemonde H, Clayton PT, Cuebas DA, Wanders RJ. Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proc Natl Acad Sci USA 1998;95:2128-2133.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
18. Itoh M, Suzuki Y, Akaboshi S, Zhang Z, Miyabara S, Takashima S. Developmental and pathological expression of peroxisomal enzymes: Their relationship of D-bifunctional protein deficiency and Zellweger syndrome. Brain Res 2000;858:40-47.
19. Van Veldhoven PP, Van Rompuy P, Fransen M, De Bethune B, Mannaerts GP. Large-scale purification and further characterization of rat pristanoyl-CoA oxidase. Eur J Biochem 1994;222:795-801.
20. Vanhooren JC, Fransen M, De Bethune B, Baumgart E, Baes M, Torrekens S, Van Leuven F, Mannaerts GP, Van Veldhoven PP. Rat pristanoyl-CoA oxidase. cDNA cloning and recognition of its C-terminal (SQL) by the peroxisomal-targeting signal 1 receptor. Eur J Biochem 1996;239:302-309.
21. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270.
22. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
23. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000;97:3450-3454.
24. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 2001;285:217-223.
25. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV, Kuhajda FP. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003;63:7330-7337.
26. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35:285-296.
27. Adamski J, Normand T, Leenders F, Monte D, Begue A, Stehelin D, Jungblut PW, de Launoit Y. Molecular cloning of a novel widely expressed human 80 kDa 17 beta-hydroxysteroid dehydrogenase IV. Biochem J 1995;311(Pt 2):437-443.
28. Baes M, Huyghe S, Carmeliet P, Declercq PE, Collen D, Mannaerts GP, Van Veldhoven PP. Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids. J Biol Chem 2000;275:16329-16336.